![]() 喹普利拉结构式
![]() |
常用名 | 喹普利拉 | 英文名 | CI928 |
---|---|---|---|---|
CAS号 | 82768-85-2 | 分子量 | 410.46300 | |
密度 | 1.289 g/cm3 | 沸点 | 674.5ºC at 760 mmHg | |
分子式 | C23H26N2O5 | 熔点 | 166-168ºC | |
MSDS | 中文版 美版 | 闪点 | 361.7ºC |
喹普利拉用途奎那普利是一种口服活性非巯基血管紧张素转换酶(ACE)抑制剂,是奎那普利的活性代谢物。奎那普利特异性阻断血管紧张素I向血管收缩剂血管紧张素II的转化,并抑制缓激肽的降解。奎那普利特作为抗高血压药和血管扩张剂[1][2]。 |
中文名 | 喹普利拉 |
---|---|
英文名 | quinaprilat hydrate |
英文别名 | 更多 |
描述 | 奎那普利是一种口服活性非巯基血管紧张素转换酶(ACE)抑制剂,是奎那普利的活性代谢物。奎那普利特异性阻断血管紧张素I向血管收缩剂血管紧张素II的转化,并抑制缓激肽的降解。奎那普利特作为抗高血压药和血管扩张剂[1][2]。 |
---|---|
相关类别 | |
体外研究 | 奎那普利(5μM)介导有机阴离子转运体3(hOAT3)的相互作用,该转运体可促进奎那普利的肾脏活性分泌,使HEK293细胞对奎那普利特的摄取增加到25倍,且hOAT3对奎那普里特的亲和力Km为13.4μM[1]。奎那普利(100nM,20min)可通过激活B1受体抑制蛋白激酶C(PKC)的活性,导致人肺微血管内皮(HLMVE)细胞释放NO[2]。 |
参考文献 |
密度 | 1.289 g/cm3 |
---|---|
沸点 | 674.5ºC at 760 mmHg |
熔点 | 166-168ºC |
分子式 | C23H26N2O5 |
分子量 | 410.46300 |
闪点 | 361.7ºC |
精确质量 | 410.18400 |
PSA | 106.94000 |
LogP | 2.41740 |
外观性状 | 结晶固体 |
危险品运输编码 | NONH for all modes of transport |
---|
喹普利拉上游产品 3 | |
---|---|
喹普利拉下游产品 0 |
Haemodynamic effects of intravenous quinaprilat in comparison to sodium nitroprusside in patients with chronic heart failure.
Int. J. Cardiol. 121(1) , 102-4, (2007) We compared the haemodynamic effects of intravenous boluses of the ACE inhibitor quinaprilat with an intravenous infusion of sodium nitroprusside in 23 patients with chronic heart failure (NYHA Class ... |
|
Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits.
J. Cardiovasc. Pharmacol. 41(6) , 938-45, (2003) This study examined whether quinaprilat, an angiotensin-converting enzyme inhibitor, reduces the infarct size, and investigated the mechanisms for its infarct size-reducing effect, in rabbits. Japanes... |
|
LC-MS/MS assay of quinapril and its metabolite quinaprilat for drug bioequivalence evaluation: prospective, concurrential and retrospective method validation.
Bioanalysis 1(1) , 71-86, (2009) The bioequivalence of two pharmaceutical formulations containing 10 mg quinapril was assessed by assaying the untransformed drug and its active metabolite quinaprilat from plasma samples.A gradient el... |
(3S)-2-[(S)-2-[[(S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid |
quinapril diacid |
ci928 |
(3s-(2(r*(r*)),3r*))-yl)amino)-1-oxopropyl) |
(3S)-2-[(S)-2-[[(S)-1-Carboxy-3-phenylpropyl]amino]propionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid |
[3S-[2[R*(R*)],3R*]]-2[2-[[1-(carboxy)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid |
CI-92 |
3-Isoquinolinecarboxylic acid,2-(2S)-2-(1S)-1-carboxy-3-phenylpropylamino-1-oxopropyl-1,2,3,4-tetrahydro-,(3S) |
3-isoquinolinecarboxylicacid,1,2,3,4-tetrahydro-2-(2-((1-carboxy-3-phenylprop |
quinaprilate |
(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid |